Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viatris (GB:0A5V)
LSE:0A5V
Viatris (0A5V) Share Price & Analysis
0 Followers
0A5V Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.55 - $13.47
Previous Close$11.36
Volume6.91K
Average Volume (3M)44.88K
Market Cap
$13.49B
Enterprise Value$30.63B
Total Cash (Recent Filing)$991.90M
Total Debt (Recent Filing)$18.13B
Price to Earnings (P/E)250.8
Beta1.08
Next Earnings
May 09, 2024EPS Estimate
$0.67Last Dividend Ex-Date
Mar 08, 2024Dividend Yield4.22%
Share Statistics
EPS (TTM)0.04
Shares OutstandingN/A
10 Day Avg. Volume1,812
30 Day Avg. Volume44,883
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.62
Enterprise Value/Gross Profit4.76
Enterprise Value/Ebitda14.80
Forecast
1Y Price Target
$12.25Price Target Upside7.36% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
Viatris News
Bulls Say, Bears Say
Bulls Say
Business StrategyCost/risk sharing deals like the Idorsia transaction could be a template for future innovative brand buildout.
Drug EfficacySelatogrel demonstrated an anti-platelet effect without increased bleeding risk in earlier trials.
Financial HealthThe company has a significant free cash flow, which allows for dividends and share repurchases.
Bears Say
Clinical Data ConcernsCenerimod for lupus lacks adequately supportive Phase 2 data compared to competitors.
Drug Development RisksSelatogrel for AMI is characterized as high risk/high reward due to complicated trial design.
Financial PerformanceEBITDA guidance for the upcoming year is below the management's previous estimates, indicating potential challenges in profitability.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.99% Insiders
23.60% Mutual Funds
29.52% Other Institutional Investors
45.88% Public Companies and
Individual Investors
0A5V FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest share price was $8.55 and its highest was $13.47 in the past 12 months.
What is Viatris’s market cap?
Currently, no data Available
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Feb 28, 2024. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.646 by -$0.026.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 4.22%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is $0.67.
How many shares outstanding does Viatris have?
Viatris has 1,187,569,100 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.62 in its last earnings report, missing expectations of $0.646. Following the earnings report the stock price went down -6.21%.
Which hedge fund is a major shareholder of Viatris?
Among the largest hedge funds holding Viatris’s share is Davis Selected Advisers. It holds Viatris’s shares valued at 679M.
---
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$12.25 (7.36% Upside)
$12.25 (7.36% Upside)
Blogger Sentiment
Bullish
GB:0A5V Sentiment 90%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.65%
12-Months-Change
Fundamentals
Return on Equity
0.26%
Trailing 12-Months
Asset Growth
-4.67%
Trailing 12-Months
Company Description
Viatris
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
---
0A5V Company Deck
---
0A5V Earnings Call
Q4 2024
0:00 / 0:00
---
0A5V Net sales Breakdown
63.69% Brands
36.31% Generics
---
0A5V Stock 12 Months Forecast
Average Price Target
$12.25
▲(7.36% Upside)
Technical Analysis
Best Analysts Covering 0A5V
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
-8.63%
reiterated a sell rating 29 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -8.63% per trade.
---